65,437 trials
Adult Alveolar Soft-part Sarcoma · Adult Angiosarcoma · Adult Epithelioid Sarcoma
Primary: Probability for Event Free Survival. — 0.8984; 0.7647; 0.6079; 0.4873 Probability of EFS at 5 years
High Risk Non-Hodgkin's Lymphoma
Primary: Assess the Efficacy of Combination Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma — 6 Participants
Depression
Primary: Comparision of the Buproprion Area Under the Concentration Time Curve (AUC) From Time 0 to 96 Hours by Type of Formulation and Dosage — 469; 667; 706; 1002…
Uterine Fibroids · Abnormal Uterine Bleeding · Pelvic Pain
Primary: Vaginal Cuff Closure Times — 10.17; 12.54 minutes
Chronic Sinusitis
Primary: Percent of Sinuses That Require Post-operative Interventions (Propel Mini Cohort) — 38.8; 62.7 percent sinuses requiring intervention
Infections, Meningococcal · Meningococcal Vaccines
Primary: Number of Subjects With Vaccine Response to N. Meningitidis Serogroups A (MenA), MenC, MenY and MenW-135 — 529; 124; 664; 210 Participants
Adult Male Hypogonadism
Primary: Percentage of Subjects With a Serum Total Testosterone Level - Maximum Observed Concentration (Cmax) of 1500-1799, 1800-2499, or Above 2500 ng/dL — 5.7; 2.8; 2.8…
Prostate Cancer
Primary: Define the PSA Response Rate. — 5; 17; 25 Participants
Renal Cell Carcinoma
Primary: Duration of Axitinib Treatment — 15.2 months
Autistic Disorder
Primary: Cognitive Assessment: TMT — 118.3; 104.7 seconds
Herpes Zoster
Primary: Cell-Mediated Immunity (CMI) in Terms of Frequencies of Antigen-specific CD4 T Cells — 726.19; 567.52 cells/million T-cells
Healthy
Primary: Prostate Tissue DHT Concentrations After Treatment — 4.05; 4.26; 2.99; 3.88 ng/g
Systemic Sclerosis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 71 Adverse Events
Bronchiolitis Obliterans
Primary: Number of Subjects Who Failed Treatment — 2 Participants
Juvenile Idiopathic Arthritis (JIA)
Primary: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and TEAEs Leading to Discontinuation (DC) of Study Drug — 4…